# NK cells in peripheral blood carry trogocytosed tumor antigens from solid cancer cells

Mauricio Campos-Mora, William Jacot, Geneviève Garcin, Marie-Lise

Depondt, Michael Constantinides, Catherine Alexia, Martin Villalba

► To cite this version:

Mauricio Campos-Mora, William Jacot, Geneviève Garcin, Marie-Lise Depondt, Michael Constantinides, et al.. NK cells in peripheral blood carry trogocytosed tumor antigens from solid cancer cells. Frontiers in Immunology, 2023, 14, pp.1199594. 10.3389/fimmu.2023.1199594. hal-04252345

HAL Id: hal-04252345

https://hal.science/hal-04252345v1

Submitted on 20 Oct 2023

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons CC BY 4.0 - Attribution - International License
<figure><img src="image_2.png" /></figure>

Check for updates

**OPEN ACCESS**

**EDITED BY**
Chiara Porta,
University of Eastern Piedmont, Italy

**REVIEWED BY**
Karine Crozat,
INSERM UMR1236 Microenvironnement,
Différenciation Cellulaire, Immunologie et
Cancer, France
Scott Wetzel,
University of Montana, United States

*CORRESPONDENCE

Martin Villalba

<figure><img src="image_3.png" /></figure>

martin.villalba@inserm.fr

RECEIVED 03 April 2023

ACCEPTED 10 July 2023

PUBLISHED 01 August 2023

**CITATION**

Campos-Mora M, Jacot W, Garcin G, Depondt M-L, Constantinides M, Alexia C and Villalba M (2023) NK cells in peripheral blood carry trogocytosed tumor antigens from solid cancer cells. *Front. Immunol.* 14:1199594.
doi: 10.3389/fimmu.2023.1199594

**COPYRIGHT**

© 2023 Campos-Mora, Jacot, Garcin, Depondt, Constantinides, Alexia and Villalba. This is an open-access article distributed under the terms of the [Creative Commons Attribution License (CC BY)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# NK cells in peripheral blood carry trogocytosed tumor antigens from solid cancer cells

Mauricio Campos-Mora¹, William Jacot², Genevieve Garcin¹, Marie-Lise Depondt¹, Michael Constantinides¹, Catherine Alexia¹ and Martin Villalba¹,³,⁴*

¹IRMB, Univ Montpellier, INSERM, Montpellier, France, ²Institut du Cancer de Montpellier (ICM) Val d'Aurelle, Montpellier University, INSERM U1194, Montpellier, France, ³IRMB, University of Montpellier, INSERM, CNRS, Montpellier, France, ⁴Institut du Cancer Avignon-Provence Sainte Catherine, Avignon, France

The innate immune lymphocyte lineage natural killer (NK) cell infiltrates tumor environment where it can recognize and eliminate tumor cells. NK cell tumor infiltration is linked to patient prognosis. However, it is unknown if some of these antitumor NK cells leave the tumor environment. In blood-borne cancers, NK cells that have interacted with leukemic cells are recognized by the co-expression of two CD45 isoforms (CD45RARO cells) and/or the plasma membrane presence of tumor antigens (Ag), which NK cells acquire by trogocytosis. We evaluated solid tumor Ag uptake by trogocytosis on NK cells by performing co-cultures *in vitro*. We analyzed NK population subsets by unsupervised dimensional reduction techniques in blood samples from breast tumor (BC) patients and healthy donors (HD). We confirmed that NK cells perform trogocytosis from solid cancer cells *in vitro*. The extent of trogocytosis depends on the target cell and the antigen, but not on the amount of Ag expressed by the target cell or the sensitivity to NK cell killing. We identified by FlowSOM (Self-Organizing Maps) several NK cell clusters differentially abundant between BC patients and HD, including anti-tumor NK subsets with phenotype CD45RARO+CD107a+. These analyses showed that bona-fide NK cells that have degranulated were increased in patients and, additionally, these NK cells exhibit trogocytosis of solid tumor Ag on their surface. However, the frequency of NK cells that have trogocytosed is very low and much lower than that found in hematological cancer patients, suggesting that the number of NK cells that exit the tumor environment is scarce. To our knowledge, this is the first report describing the presence of solid tumor markers on circulating NK subsets from breast tumor patients. This NK cell immune profiling could lead to generate novel strategies to complement established therapies for BC patients or to the use of peripheral blood NK cells in the theranostic of solid cancer patients after treatment.

**KEYWORDS**

NK cells, t-SNE, trogocytosis, breast cancer, CD45
<figure><img src="image_4.png" /></figure>

GRAPHICAL ABSTRACT

Human NK cells that encounter cancerous cells uptake epithelial antigens (Ag) and can be identified on blood of breast tumor patients comprising specific NK subsets.

Introduction

Natural killer (NK) cells are a subset of lymphoid cells and part
of the innate immune compartment. As blood-circulating cells with
cytotoxic activity, NK cells screen for damaged or stressed cells, and
they are readily able to kill virus-infected or transformed tumor
cells, contributing to immune surveillance (1). These cells are
mainly classified as CD56+CD3- innate lymphoid cells, but they
constitute a heterogeneous population comprising NK cell subsets
with different cytotoxic potential. Based on CD56 and CD16 surface
expression, they subdivide into CD56<sup>+</sup>CD16<sup>high</sup> blood-circulating
NK cells, with stronger cytotoxic activity after target cell
recognition, and CD56<sup>high</sup>CD16<sup>low</sup> cells cytokine-producing NK
cells with poor cytolytic activity, mostly present in secondary
lymphoid tissues (2). However, recent studies have challenged
this classical view, and high dimensionality, single-cell proteomic
analysis have revealed a striking NK cell phenotype diversity, which
might be influenced by both genetic differences between individual
humans and environmental conditions (3). Considering that NK

cell function is tightly modulated by the expression of several
inhibitory and activating receptors, the determination of NK cell
subsets repertoire and their contribution to physiological processes
could be of paramount importance for generation of NK cell-based
therapies against malignant diseases (4, 5).

The anti-tumor properties of NK cells have been previously discussed (6). NK cells play an essential role in tumor clearance by recognizing and killing abnormal tumor cells without the need of prior activation. After recognition of target cells, different target cell-derived proteins can be acquired in NK cell membrane surface in a cell-to-cell contact-dependent manner, a process called trogocytosis (7–11). Trogocytosis involves an intercellular transfer of membrane patches, and it has been shown to occur in different immune cell types, albeit the physiological relevance of this process is not fully understood (9, 11–13). This transference of functional proteins to cell surface could modulate NK function *in vitro* and *in vivo* (14–20). Trogocytosis is receiving high interest from the clinic for this possibility to modulate NK cell (18, 20) or CAR T cell function (21, 22).

We have reported the identification of NK cell populations with anti-tumor activity in hematological cancer patients (23–26). The highly activated CD56+CD16<sup>high</sup> NK cells found in these patients exhibit the expression of activation markers, such as NKp46 and NKG2D, and low expression levels of inhibitory markers, such as NKG2A and CD94. Interestingly, these NK cells also present non-NK, tumor cell-derived antigens on their surface, which can be an indicative of trogocytosis during cell killing (23–26). We found that this subset of anti-tumor NK cells is also characterized by degranulation and co-expression of both CD45RO and CD45RA (CD45RARO cells) (23–26). Further high-dimensionality, multiparametric flow cytometry and unsupervised analyses in multiple hematological tumor patients showed that NK subsets

**Abbreviations:** Ag, antigens; BC, breast cancer; CITRUS, cluster identification, characterization and regression; CytD, cytochalasin D; EBV, Epstein-Barr Virus; eNK, expanded human NK cell; EpCAM, epithelial cell adhesion molecule; FBS, fetal bovine serum; FDR, false discovery rate; HD, healthy donor; HER2, human epidermal growth factor receptor 2; MUC1, mucin-1; NK, natural killer cell; PBMC, peripheral blood mononuclear cells; PBS, phosphate buffer saline; PDL, poly-D-lysine; PD1, programmed cell death protein 1; PSMA, prostate-specific membrane antigen; SAM, significance analysis of microarrays; SOM, self-organizing maps; TNBC, triple-negative breast cancer; t-SNE, t-stochastic neighbor embedding; UCB, umbilical cord blood; UCBMC, UCB mononuclear cells; viSNE, Barnes-Hut implementation of t-SNE.
presenting CD45RARO phenotype and evident tumor-antigen derived trogocytosis responds directly to the oncologic status of patients, which suggest that the frequency of the function of these NK subsets depend of the presence of targets (23, 24).

NK cells infiltrate solid cancers, as well as tumor-infiltrated lymph nodes and metastases (27-29). NK cell infiltration of most solid tumor is rather sparse and depends on tumor localization and the nature of the cancer (30). To our knowledge, detection of anti-tumor NK cell subsets expressing trogocytosed tumor-derived markers in peripheral blood of solid tumor patients have not been reported. Here we investigated whether NK cells could acquire solid tumor antigens by trogocytosis *in vitro* and *in vivo*. Additionally, we studied the presence of anti-tumor, blood-circulating, NK cells subsets exhibiting these solid tumor antigens in breast cancer patients by multiparametric flow cytometry and high-dimensionality unsupervised analyses.

# Patients, materials and methods

## Ethical statement

The use of human specimens for scientific purposes was approved by the French National Ethics Committee. All methods were carried out in accordance with the approved guidelines and regulations of this committee. Written informed consent was obtained from each patient or donor prior to collection.

## Breast tumors patients

Data and samples from patients were collected at the Institute for Cancerology of Montpellier (ICM), France, after patient's

written consent and following French regulations. Patients were enrolled in the ICM-BDD 2017/37 (ID-RCB: 2017-A01940-53) clinical program approved by the "Comités de Protection des Personnes Sud-Ouest et Outre-Mer III" with the reference 2017/45. Blood samples were collected at diagnosis. Peripheral blood mononuclear cells (PBMCs) were obtained by Ficoll® gradient and stored frozen in liquid nitrogen until use. Patients' status is described in Table 1.

## Healthy donor

HD samples were obtained from written informed donors, collected by clinicians of the CHU Montpellier and collected and processed as the patient's samples.

## Cell lines

Breast cancer cell lines BT-20, SKBR3 and MDA-MB-468, pancreatic adenocarcinoma cell line LNCaP, colorectal adenocarcinoma cell line HCT116, and the Epstein-Barr Virus (EBV)-transformed lymphoblastoid B cell line PLH were grown in RPMI 1640 media (Gibco) supplemented with 10% fetal bovine serum (FBS). Cells were used for experiments at confluency of ~80%. Cell line identity was confirmed by flow cytometry when possible, and cells were regularly tested for mycoplasma.

## UCBMC purification

Umbilical cord blood (UCB) units obtained from healthy donors from CHU Montpellier. UCB mononuclear cells

<table><caption>TABLE 1 Description of patients.</caption><thead><tr><td>Patient Number</td><td>Pathology</td><td>Estrogen Receptor (%)</td><td>Progesterone Receptor (%)</td><td>HER2 Overexpression</td><td>Patients ER/PR Receptor status</td><td>Clinical Status</td></tr></thead><tbody><tr><td>1</td><td>Breast cancer</td><td>0</td><td>0</td><td>3+</td><td>-</td><td>Alive</td></tr><tr><td>2</td><td>Breast cancer</td><td>100</td><td>70</td><td>2+/FISH-</td><td>+</td><td>Alive</td></tr><tr><td>3</td><td>Breast cancer</td><td>100</td><td>100</td><td>1+</td><td>+</td><td>Alive</td></tr><tr><td>4</td><td>Breast cancer</td><td>100</td><td>70</td><td>0</td><td>+</td><td>Alive</td></tr><tr><td>5</td><td>Breast cancer</td><td>90</td><td>90</td><td>1+</td><td>+</td><td>Alive</td></tr><tr><td>6</td><td>Breast cancer</td><td>60</td><td>30</td><td>1+</td><td>-</td><td>Alive</td></tr><tr><td>7</td><td>In situ breast cancer carcinoma</td><td>ND</td><td>ND</td><td>ND</td><td>-</td><td>Alive</td></tr><tr><td>8</td><td>Breast cancer</td><td>95</td><td>5</td><td>2+/FISH-</td><td>+</td><td>Alive</td></tr><tr><td>9</td><td>Atypical ductal hyperplasia</td><td>ND</td><td>ND</td><td>ND</td><td>-</td><td>Alive</td></tr><tr><td>10</td><td>Breast cancer</td><td>100</td><td>5</td><td>2+/FISH-</td><td>+</td><td>Alive</td></tr></tbody></table>

Blood samples were collected from patients and PBMCs were frozen until use. The clinical status of the patients is depicted regarding expression of estrogen and progesterone receptors and HER2 status (0, 1+, 2+/FISH- are, altogether "HER2-negative", and 2+/FISH+ and 3+ are "HER2-positive". Patients 7 and 9 were included in this study, but were not considered per se cancers. Patient 7 developed an *in situ* carcinoma and consequently ER, PR and HER2 were not tested. Patient 9 showed atypical ductal hyperplasia at recruitment, indicative of an increased risk of cancer, and, indeed, the patient developed invasive cancer the following year. ER, PR and HER2 are typically not tested in this population. The column "Patient Receptor status" describes the patients who are considered in the group of receptor-negative patients (-) or receptor-positive patients (+).

FISH, fluorescence *in situ* hybridization; ER, estrogen receptor; HER2, human epidermal growth receptor 2; ND, not determined; PR, progesterone receptor.
(UCBMC) were collected from UCB units using Ficoll® Paque Plus (Sigma) by density gradient centrifugation. Briefly, one volume of Ficoll® Paque Plus were added to conical tubes, and two volumes of blood (previously diluted 1:1 with RPMI media) were slowly deposited at the top. Tubes were centrifuged at 425 x g for 30 min at room temperature, without brake. Mononuclear cells were collected from buffy coat layer, washed in RPMI and resuspended in RPMI media supplemented with 10% FBS.

## Enrichment, activation and expansion of human NK cells

Expanded NK (eNK) cells were obtained as previously described (31-34). Briefly, UCBMC were depleted of T cells by using EasySep™ CD3 Positive Selection Kit II (STEMCELL Technologies). Cells were cultured in the presence of γ-irradiated PLH cells at ratio NK-to-accessory cell of 1:1 in RPMI 10% FBS media supplemented with human IL-2 (100UI/mL, Peprotech) and human IL-15 (5 ng/mL, Miltenyi Biotec) for 14-to-21 days. Once every 3 days, cells were counted and fresh culture media with FBS, IL-2 and IL-15 was added to the culture, along with additional γ-irradiated PLH cells. Purity of human CD3-CD56+ eNK cells at the end of the culture was always ≥ 90%.

## Trogocytosis *in vitro* and staining

Adherent tumor cells were seeded in 48-well flat-bottom plates (200,000 cells/mL in culture medium) and incubated overnight at 37° C. Trogocytosis *in vitro* of tumor markers was attained by co-culturing eNK cells (acceptor cells) with BT20, LNCaP, SKBR3, MDA-MB-468 or HCT116 (donor cells) in several acceptor-to-donor ratios. For experiments under inhibition of actin recruitment, eNK cells were previously treated with 2 µg/mL cytochalasin D (CytD, Sigma-Aldrich) for 30 min at 37°C. In experiments where Src kinase was inhibited, NK cells were pretreated with 10 µM PP2 (Sigma) for 10 min and then maintained during the co-culture. NK cells were also co-cultured with tumor cells at 4°C as a control. For membrane dye transfer experiments, SKBR3 or MDA-MB-468 cells were stained with Vybrant™ DiD Cell-Labeling Solution (Invitrogen) for 20 min, and then co-cultured with NK cells. Plates were centrifuged at 150 x g for 30 seconds to favor cell contact, and cells were incubated at 37°C for 2 h or overnight (16 h). After trogocytosis, eNK cells were recovered and washed several times in FACS buffer (PBS, 2% FBS). For experiments to measure tumor marker trogocytosis, cells were stained for surface markers with the following fluorochrome-coupled antibodies: CD56-V450; CD19-ECD; HER2-PE (all from BD); CD16-KO (Beckman); CD3-APC; CD335-PE-Vio770; CD45RO-FITC; CD45RA-APC-Vio770; and PSMA-PE or EpCAM-PE (all from Miltenyi Biotec). For experiments to determine measuring membrane dye transfer, cells were for surface markers with the antibodies CD56-V450 and CD3-FITC (all from BD). Cell viability was determined using 7-AAD exclusion (Miltenyi Biotec). Staining was performed in FACS buffer at 4°C for 25-30 min, and then cells were washed three times before

FACS acquisition and analysis in Gallios flow cytometer instrument (Beckman Coulter). After exclusion of doublets and dead cells, tumor marker detection on CD3-CD56+CD335+ NK cells was evaluated by analyzing FCS files using FlowJo software v10.6.1 (Tree Star Inc.).

## Trogocytosis *ex vivo*

In brief, healthy donors and patient's total peripheral blood mononuclear cells (PBMC) were stained for surface markers with the following fluorochrome conjugated antibodies: CD4-BUV737, CD56-BUV395, CD3-BV786, CD16-BV711, CD7-BV421, HER2-BV650, CD326-BV605, PD1-FITC, MUC1-PerCP, CD107a-PE-CF594, CD14-AF700, CD19-AF700, PSMA-PE, CD45RO-VioGreen, NKp46-PE-Vio770, CD45RA-APC-Vio770 and CD138-APC (all from Miltenyi Biotec). Cell viability was determined using DAPI exclusion (BD Biosciences). Cells were stained with antibodies cocktail in FACS buffer at 4°C for 25-30 min and washed twice with the same FACS buffer and acquired on BD LSR-Fortessa instrument (Blue-Yellow/Green-Red-Violet-Ultraviolet) (BD Bioscience). FCS files were analyzed using FlowJo software v10.6.1 (Tree Star Inc.).

## Fluorescence microscopy

Breast cancer cell line SKBR3 cells were seeded in 24-well flat-bottom plates (200,000 cells/mL in culture medium) on coverslips previously coated with poly-D-lysine (Sigma), and incubated overnight at 37°C. Trogocytosis *in vitro* of tumor markers was attained by co-culturing eNK cells (acceptor cells) with SKBR3 (donor cells) in effector-to-target ratio of 1:1, leaving some coverslips with eNK alone. Cells were incubated overnight at 37° C and after media removal and wash with PBS, attached cells were fixed using 4% paraformaldehyde diluted in PBS and blocked with 5% FBS diluted in PBS. Cells were then incubated with CD56-AlexaFluor™488 and CD326-PE antibodies (all from BD Biosciences) diluted in blocking solution for 2 h at room temperature, protected from light. Some coverslips with eNK cells were stained with CD45-PE antibody (Beckman) diluted in blocking solution. Hoescht 33342 was used for nucleus staining. After several washing steps, coverslips were mounted on microscope glass slides using Prolong Gold mounting media (ThermoFisher). Cell samples were visualized using a Leica SP5 fluorescence microscope (Carl Zeiss, Germany) and images analyzed using the Las X Life Science software (Carl Zeiss).

## High dimensional reduction analysis

To generate tSNE or UMAP embedding, a pre-gated NK cell population from each sample with the same number of cells per patient and timepoint was selected using FlowJo Downsample plugin (v3.1.0) and merged before uploading in the Cytobank cloud-based platform (Cytobank, Inc.). High-dimensional single-cell data dimensionality reduction was performed by viSNE, which is based
upon the t-Distributed Stochastic Neighbor Embedding (t-SNE) implementation of Barnes-Hut (35). viSNE was used to visualize FACS data as 2D t-SNE maps, using the following parameters: Desired Total Events (Equal sub-sampling): 50.000; Channels: selected all 16 surface markers; Compensation: “File-Internal Compensation”; Iterations: 1000; Seed; “Random”; Theta: 0.5. FlowSOM was used with default settings unless otherwise noted. FlowSOM uses Self-Organizing Maps (SOMs), based on marker expression phenotype, to assign all individual cells into clusters and metaclusters (that is, group of clusters) (36). FlowSOM was performed with the following parameters: Event Sampling Method: “Equal”; Desired events per file: “2.736”; Total events actually sampled: “27.160”; SOM Creation: “Create a new SOM”; Clustering Method: “Hierarchical Consensus”; Number of metaclusters: “12”; Number clusters: “256”; Iterations: “100”; Seed: “4567”. CITRUS (cluster identification, characterization, and regression) is an algorithm designed for the discovery of statistically significant stratifying biological signatures within single cell datasets containing numerous samples across associated conditions or correlated with clinical phenotype of interest (e.g. responders versus non-responders) (37). The output is a network topology of cell subpopulations divided in sub-clusters that represents a hierarchical stratification of the original sample. Median expression levels of functional markers measured across each population can drive the differentiation between phenotypes. CITRUS was performed using the Significance Analysis of Microarrays (SAM) correlative association model (Benjamin-Hochberg-corrected *P* value, false discovery rate (FDR) < 0.01), with the following parameters: Clustering channels: “selected all surface markers except CD107a and tumor markers”; Compensation: “File-Internal Compensation”; Statistic channels: “CD107a and tumor markers”; Association Models: “Significance Analysis of Microarrays (SAM) – Correlative”; Cluster Characterization: “Medians”; Event sampling: “Equal”; Event sampled per file: “2000”; Minimum cluster size (%): “1”; Cross Validation Folds: “5”; False Discovery Rate (%): “1”. Identification of NK cell subsets between the group “Healthy Donors” and “Breast Cancer patients” was performed by comparing the relative expression of CD107a and tumor markers of the specified FlowSOM metacluster.

## Statistical analysis

Experimental figures and statistical analysis were performed using GraphPad Prism (v8.0). All statistical values are presented as * p<0.05; ** p<0.01; *** p<0.001 and **** p<0.0001. Mean values are expressed as mean plus or minus the standard error of the mean (SEM).

## Results

### NK cells perform **trogocytosis** *in vitro* on solid tumor cells

The breast cancer cell lines BT-20 and SKBR3, the human prostate adenocarcinoma cell line LNCaP and the human colon

cancer cell line HCT116 lack expression of CD3 (T cell marker) and CD56 (NK cell marker) and show very low expression of CD335 (NK cell marker), also known as NKp46/NCR1 (Figure S1). In contrast, they do express human epidermal growth factor receptor 2 (HER2) and Epithelial cell adhesion molecule (EpCAM or CD326).

We expanded NK cells (eNK) *in vitro* as previously described (31–34) and incubated them with BT-20, SKBR3 and LNCaP cell lines. All these cell lines were sensitive to eNK cell killing (Figures S2A, B).

As expected, eNK do not express HER2 or prostate-specific membrane antigen (PSMA) (Figure 1A). When eNK were incubated with BT-20 and SKBR3 cells, they gained HER2 expression (Figure 1A), although the levels were 10 times lower than those found in target cells (Figures S1, 1B). eNK also gained PSMA when incubated with LNCaP cells that largely express this Ag (Figures 1A, C). Again, the expression of PSMA was 10 times lower for eNK than for LNCaP (Figure 1C). Optimal trogocytosis on all cell lines was observed at 3:1 E:T ratio (Figures 1D, S3). Of note, eNK encountering BT-20 cells acquire less HER2 expression than those encountering SKBR3 (Figure 1A, S3), although the tumor cell sensitivity to NK cytotoxicity was similar (Figure S2).

After confirming that NK cells can capture tumor antigens from solid cancer cells, we wanted to elucidate whether this gaining of expression was caused by trogocytosis. For this objective, as trogocytosis is a very rapid process, we restricted our co-cultures down to 2 h of incubation (38, 39). There is a lack of specific inhibitors for trogocytosis, but it has been described its interference by disruption of actin polymerization, inhibition of kinases (such as Src-kinase and Syk-kinase) and low temperature (4°C) (40, 41). Before performing the co-culture with SKBR3 tumor cells, we pre-treated eNK cells with cytochalasin-D (CytD) for inhibition of actin recruitment, or incubated the cells in the presence of PP2 for inhibition of Src-tyrosine kinase, which resulted in a decrease of HER2 acquisition by NK cells (Figure S4A). Moreover, we carried out these co-cultures at 4°C which completely reduced tumor marker acquisition (Figure S4B). We complemented these observations by using MDA-MB-468 as breast cancer donor tumor cells, which are negative for HER2 in comparison to SKBR3 (Figure S4C). Consistent with the idea that HER2 is acquired from donor cells via trogocytosis, NK cells co-cultured with MDA-MB-468 cells at different ratios did not increase HER2 expression after incubation (Figure S4D). However, this result would not be due to the absence of trogocytosis from this cell line, as we confirmed by membrane dye transfer experiments, in which NK cells were co-cultured with SKBR3 or MDA-MB-468 breast tumor cells previously labeled with the lipid intercalant dye DiD (Figure S4E). Even only after 2 h of co-culture, NK cells became strongly positive for this dye, and pre-treatments with CytD and PP2 along with 4°C incubation blocked the acquisition of donor membrane lipids from NK cells (Figure S4E). Considering that transfer of proteins via trogocytosis goes together with transfer of membrane lipids, altogether these results suggest that HER2 and other solid tumor markers are acquired by NK cells via trogocytosis.

To further confirm that eNK cells captured tumor cell-expressed receptors by trogocytosis, we analyzed the interaction between solid tumor cells (donor cells) and eNK cells during co-
<figure><img src="image_5.png" /><figcaption>FIGURE 1</figcaption></figure>

NK cells acquire HER2 and PSMA from solid tumor cells. NK cells expanded *in vitro* (eNK) were incubated overnight with different solid tumor cells. After excluding doublets and dead cells, the surface expression of HER2 (for co-culture with BT-20 or SKBR3 cells) and PSMA (for LNCaP cells) were analyzed on live CD56+CD335+ eNK cells by flow cytometry. (A) Expression of HER2 or PSMA on eNK incubated alone or co-cultured at E:T 3:1 with the depicted cell lines. (B) Top, histograms show HER2 expression on SKBR3 and BT-20 cell lines. Bottom, HER2 expression level on eNK cells alone or co-cultured at E:T 3:1 with tumor cells. (C) Top, histograms show PSMA expression on LNCaP cell line. Bottom, PSMA expression level on eNK cells alone or co-cultured at E:T 3:1 with LNCaP cells. (D) The percentage of eNK carrying HER2 or PSMA is depicted in the graph (bars represent mean ± SEM). Statistical significance between eNK alone condition and the different E:T ratios were determined by two-way ANOVA (Tukey's test), n = 5 independent experiments, \* *p* ≤ 0.05; \*\*\* *p* ≤ 0.001. ns, not significant.

culture by the approach of fluorescence microscopy. As expected, we observed that eNK cells were positive for CD56 and CD45, and negative for EpCAM (Figures 2A, B), while solid tumor cells SKBR3 (donor cells) expressed EpCAM (CD326, Figure 2C). eNK co-cultured with SKBR3 cells interacted with them by forming immune synapses and performing cytotoxicity. After trogocytosis *in vitro*, eNK acquired surface expression of EpCAM. (Figure 2D), which was absent in NK cells incubated alone. This surface expression was still evident after several washing steps (Figure 2D).

We next investigated if different Ags were differently uploaded from the same targets. eNK efficiently gained EpCAM, but much less HER2, from HCT116 or LNCaP cells (Figure 3), whereas these

cells express substantial amounts of both Ags (Figure S1). But this difference does not depend on HER2, because both HER2 and EpCAM are efficiently uploaded from SKBR3 cells (Figure 3). In summary, the efficiency of trogocytosis is variable regarding to the target cell, the efficiency of killing and the type of Ag.

## Identification of trogocytosis ex vivo

We used a cohort of patients operated for a breast tumor (8 invasive breast cancers, one ductal *in situ* carcinoma, one atypical ductal hyperplasia) to analyze several phenotypic markers on
<figure><img src="image_6.png" /><figcaption>FIGURE 2</figcaption></figure>

eNK cells capture solid tumor cell antigens *in vitro*. *In vitro* expanded NK cells (eNK) were incubated overnight alone or with SKBR3 solid tumor cells and, after antibody staining, the expression of several markers was analyzed by fluorescence microscopy. (A) eNK cells were stained with PE-conjugated anti-CD45 (red) and AlexaFluor®488-conjugated anti-CD56 (green) antibodies. The nucleus was stained with Hoescht (blue). (B) eNK cells were stained with PE-conjugated anti-CD326 (red) and AlexaFluor®488-conjugated anti-CD56 (green) antibodies. The nucleus was stained with Hoescht (blue). (C) SKBR3 cells were stained with PE-conjugated anti-CD236 (EpCAM, red) antibodies and Hoescht. (D) eNK cells co-cultured with SKBR3 cells at E:T ratio of 1:1 were stained for CD326 and CD56 as previously described. The representative micrograph panel show acquisition of CD326 expression by eNKs (yellow) via trogocytosis (white arrows). Scale bars (white): 20 µm.

peripheral NK cells. We collected and analyzed blood samples at diagnosis and compared them to NK cells of a cohort of 5 healthy donors (HD) by multiparametric flow cytometry (Figure S5). Cancer patients expressed different values of estrogen and progesterone receptors and few of them overexpressed HER2. For future analysis in this manuscript, we could independently analyze patients with high expression of estrogen and/or progesterone receptors (patients 2, 3, 4, 5, 8, 10; receptor-positive or Receptor+ or R+) and those with low or unknown expression (patients 1, 6, 7, 9; receptor-negative or Receptor- or R-). Of note, estrogen and progesterone receptors are nuclear proteins and hence, NK cells should not perform trogocytosis on them.

The percentage of CD7⁺ cells, which mainly include T and NK cells tended to decrease in patients; and in fact, the percentage of CD56⁺ cells decreased (Figures 4A, B). However, the CD56⁺/CD16⁺ cells, which represents the mature NK cells, remained stable (Figure 4C). The CD56⁺ cell subset that decreased were CD3⁺

and should represent NK T cells (Figure 4D). In contrast, the CD56⁺/CD3⁻ population, which represents NK cells, remained stable.

In hematological cancers, the main antitumor NK cell population is recognized by the expression of CD45RO (CD45RO cells), generally together with CD45RA (CD45RARO cells (23–26)); We observed a small, but significant, increase of this CD45RARO population in peripheral blood NK cells of patients (Figure 4E). This was associated with a decrease in cells expressing low CD45RA levels (CD45RAdim) and CD45RO (CD45RAdimRO cells). On the other side, the CD45RO⁺ NK subset frequency was found similar between BC patients and HD (Figure 4E).

We next evaluated degranulation, i.e. CD107a⁺ cells, in the lymphoid, i.e. CD7⁺, compartment and observed an increase in patients (Figure S6A). Exclusion of CD14⁺/CD19⁺ cells did not change our observation (Figure S6B). The differences were not statistically different when we focused on receptor-negative patients
<figure><img src="image_7.png" /><figcaption>FIGURE 3</figcaption></figure>

Different Ags are differently trogocytosed from different cell lines. *In vitro* expanded NK cells (eNK) were incubated alone or at different effector: target (E:T) ratios with solid tumor cells, and after exclusion of doublets and dead cells, the surface expression of HER2 and EpCAM was analyzed on live CD56+CD335+ NK cell population. (A) Representative histograms depict EpCAM (CD326) and HER2 expression on eNK cells. (B, C) Bars represent mean ± SEM of n = 4 independent experiments. Statistical significance between untreated cells and different E:T ratios were determined by two-way ANOVA (Tukey's test); *** *p* ≤ 0.001. ns, not significant.

(Figure S6C) and hence, the increase mainly relied in receptor-
positive patients (Figures S6D, E). Analysis of bona fide
CD7⁺CD56⁺CD3⁻ NK cells (42) confirmed the higher
degranulation of NK cells in BC patients (Figure 4F).

We analyzed trogocytosis of 4 endothelial/tumor markers, which are not expressed by NK cells. These were: HER2 (human epidermal growth factor receptor 2, which is overexpressed in certain patients), CD326 (EpCAM), Mucin 1 cell surface associated (MUC1) and PSMA. The membrane localization of all these proteins makes them candidates to be trogocytosed and exposed in NK cell plasma membrane. Patients showed higher trogocytosis of all markers except EpCAM (Figure 5A), suggesting that this Ag is not well uptaken by NK cells in vivo. However, differences were not statistically significant in the total NK cell population (Figure 5B), nor in the cells that had degranulated (Figure 5C). Notably, when we focused the analysis on receptor-positive patients, the frequency of total CD7+CD56+ NK cells exhibiting the tumor markers MUC1 and HER2 appeared to be increased (Figure 5D). The percentage of cells that have performed trogocytosis on the epithelial markers was significantly higher in CD107a⁺ NK cells than in the bulk of NK cells, principally in patient's samples (Figure S6F). We also observed this increase in CD45RARO cells regarding the bulk of NK cells (Figure S6G). However, we did not observe significant differences between HD NK CD45RARO+ and BC NK CD45RARO+ populations, nor between CD45RARO+CD107a⁺ NK cells from both groups (Figure S6H). This indicates that CD45RARO and CD107a⁺ cells

are the NK cell populations that are interacting with target cells and
recovering antigens by trogocytosis. Although there were not
significant differences between receptor-negative BC patients and
HDs, some of the tumor markers analyzed were found upregulated
on CD7+CD56+ NK cells from receptor-positive BC patients when
compared with HD (Figure 5D). The fact that HDs show a similar
pattern suggests that NK cells can interact and probably kill
endothelial cells, which could be stress or damaged cells.

Differential trogocytosed-receptor
expression pattern in NK cell
subsets between BC patients and
healthy donors by viSNE

In order to further characterize the expression of these tumor
markers present on NK cell surface due to trogocytosis, we used the
high-dimensional reduction algorithm viSNE (for visualization of t-
Distributed Stochastic Neighbor Embedding or t-SNE) (35, 43). By
viSNE, we generated unsupervised 2D t-SNE maps showing the
expression of 12 surface markers on NK cells from BC patients and
healthy donors (Figure S7). The resulting t-SNE maps exhibit
several spatial regions with differences in marker expression,
suggesting that NK cell subsets with different abundance and
expression of those markers were present.

To evaluate the differences in NK cell subset distribution
between BC patients and healthy donors, we applied the
A

<figure><img src="image_8.png" /></figure>

B

<figure><img src="image_9.png" /></figure>

C

<figure><img src="image_10.png" /></figure>

D

<figure><img src="image_11.png" /></figure>

E

<figure><img src="image_12.png" /></figure>

F

<figure><img src="image_13.png" /><figcaption>FIGURE 4</figcaption></figure>

Phenotype analysis of peripheral NK cells analyzed by manual gating. Blood samples from healthy donors (HD) and breast tumor (BC) patients were analyzed by FACS for expression of lymphoid and NK cell subset markers. Graphs represent compiled data of (A) frequency of live CD7+ cells; (B) frequency of live total CD56+ cells and (C) frequency of live total CD56+CD16+ cells. (D) Frequency of live CD56+CD3- or CD56+CD3+ between HD and BC patients. (E) Frequency of live CD3-CD4-CD7+CD56+ NK subsets based on CD45RA and CD45RO expression between HD and BC patients. (F) Expression of CD107a on live CD3-CD4-CD56+CD7+ NK cells. Graphs represent mean ± SEM; statistical significance between HD (n = 5) and BC (n = 10) was determined by Student t-Test (A-C, F) or two-way ANOVA (D, E); \* *p* ≤ 0.05; \*\* *p* ≤ 0.01. ns, not significant.

FlowSOM method which uses Self-Organizing Maps (SOMs) to cluster together cell events based on clustering channels (markers) and assign them to metaclusters, grouping them into distinct populations by an unsupervised approach (36). By this method we identified twelve metaclusters, of which two, i.e. 8 and 12, were found to be differentially abundant between BC patients and healthy donors (Figures 6A, B, Table S1). Both mainly consisted in NK cells with phenotype CD56⁺CD16highCD45RA⁺ CD107a⁺ and tumor markers expression (Table S1), Metacluster-8 was found enriched in BC patients in comparison with healthy controls and contained CD45RO⁺ cells (10.7% versus 6.9% of control, p<0.05) (Figure 6B). This difference was even more evident when we compared receptor-positive patients with healthy controls (12.4% versus 6.9% of control, p<0.01) (Figure S8A, Table S1). On the other side, metacluster-12 was found to be decreased in BC patients

compared to healthy donors (15.5% versus 19.5% of control, p<0.05). This difference was higher when controls were compared with receptor-negative patients (13.2% versus 19.5% of control). In contrast to metacluster-8, this metacluster-12 mostly comprised CD45RO⁻ NK cells (Table S1).

When we analyzed the degranulation on NK cells, we found that CD107a expression levels on Metacluster-7, Metacluster-8 and Metacluster-12 were significantly higher in BC patients compared to controls (Figure 6C). CD107a+ was also found increased in NK cells from Metacluster-10 when comparing receptor-positive BC patients and healthy donors (Figure S8B). Thus, considering that NK cells having a CD45RARO/CD107a+ phenotype previously exhibited higher degree of presumed trogocytosed proteins, we analyzed the expression levels of these solid tumor markers on these metaclusters. Interestingly, among all FlowSOM-identified
<figure><img src="image_14.png" /><figcaption>FIGURE 5
Circulating NK cells exhibit trogocytosis of solid tumor-expressed markers. Blood samples from healthy donors (HD) and breast cancer (BC) patients were analyzed by FACS for expression of tumor cell markers on CD7+CD56+ NK cell subsets. (A) Representative dot plots showing expression of tumor markers in circulating NK cells. (B) Frequency of NK cells presenting surface expression of HER2, CD326 (EpCAM), MUC1 or PSMA between HD and BC patients. (C) Frequency of trogocytosed markers on CD107+ NK cells. (D) Frequency of NK cells presenting surface expression of tumor markers in Receptor-positive patients (BC R+) versus HD. Graphs represent mean ± SEM; statistical significance between HD (n = 5) and BC (n = 10), BC-R+ (n = 6) and BC-R- (n = 4) was determined by two-way ANOVA (B-D); \* *p* ≤ 0.05. ns, not significant.</figcaption></figure>

metaclusters, we found that NK cells contained in Metacluster-8 showed the higher levels of tumor markers and, compared to healthy controls, BC patients exhibited significantly higher levels for the tumor markers CD326 and PSMA (Figure 6C). Moreover, HER2 was found particularly increased on NK cells from Metacluster-8 of receptor-positive BC patients in comparison to healthy donors (Figure S8B). Lastly, the expression of the immune checkpoint receptor programmed cell death-1 protein (PD1) was also analyzed on these NK cells, and when we compare its expression between healthy control and BC samples (total or receptor-positive patients), there was not significative difference between both groups (Figures 6C, S8B). Altogether, these results

suggest that bona-fide NK cells with an activated phenotype (CD107+ CD45RARO) are found increased on BC patients and, additionally, these NK cells exhibit high degree of potentially trogocytosed tumor markers on their surface.

To complement these observations with FlowSOM analyses, we further examinate the cell activation and trogocytosis profile of BC patients and controls, focusing on NK cells contained in Metacluster-8 and using CITRUS (37). This algorithm allows the identification of stratifying sub-populations in multidimensional flow cytometry datasets, and can be used to distinguish single-cell signatures that might be associated with clinical outcomes (44). Among NK cells in Metacluster-8, CITRUS identified a total of 153
<figure><img src="image_15.png" /><figcaption>**FIGURE 6**
Identification of NK cell clusters with acquired tumor markers by FlowSOM. FACS samples from 5 healthy donors and 10 BC patients were concatenated and randomly subsampled into 100.000 total events which were analyzed by t-SNE and displayed using viSNE. (A) FlowSOM-identified twelve metaclusters visualized in the concatenated file. To the right, metacluster-derived gating applied to concatenated HD and BC patient samples. Differences in color on the viSNE map correspond to cell abundance density. (B) Comparison of relative frequency of each FlowSOM metacluster between HD and BC patients. (C) Median fluorescence intensity (MFI) of CD107a, PD1 and trogocytosed tumor markers expressed on CD7+CD56+ NK cells present on selected metaclusters (7, 8 and 12). Graph represent box and whiskers (Min to Max), and statistical significance between HD (n = 5), BC (n = 10) was determined by two-way ANOVA; \* *p* ≤ 0.05; \*\* *p* ≤ 0.01. ns, not significant.</figcaption></figure>

clusters, of which four were found to be statistically associated to the BC patient's group, in accord to their CD107a and tumor marker expression (Figures 7A-D). By associating this CITRUS map with maps showing surface phenotype markers intensities (Figure 7E), we could identify these clusters specifically as subsets of CD56+ NK cells expressing high levels of CD16, CD45RA, NKp46 and intermediate levels of CD45RO, with high expression of CD326, PSMA, HER2 and MUC1 (Figure 7).

## Discussion

Individual humans have their own NK cell repertoire, which changes during development and is different in diverse tissues. In addition, multifactorial environmental events affect NK cells and generate new subsets (45) and make challenging to identify NK populations associated to a specific disease and shared by multiple patients. Conventional NK cells, which should correlate with the
population that we have studied, have a short half-life (5, 46). Hence, the amount of NK cells that has infiltrated the tumor and interacted with targets, then performed trogocytosis and came back to the blood stream should be scarce. In this current work, we have found a very low number of NK cells carrying tumor Ags, showing that their numbers are very low or, alternatively, to find and identify them is extremely difficult. Moreover, we observed that NK cells

from HD also carry some Ags typical of endothelial cells that we have used as trogocytosis markers. Probably, these NK cells have interacted with “stressed” endothelial cells. In case of breast cancer patients, the amount of “stressed” endothelial cells should be larger, because tumor cells are supposed to be stressed and recognized by NK cells, increasing the portion of NK cells that carry endothelial markers. However, most of the NK cells that have interacted with

<figure><img src="image_16.png" /></figure>
tumor cells should be in the tumor microenvironment as shown previously (47). Here we show that effectively their frequency in periphery is very low, and to find differences between HD and patients we needed to unveil new populations (Figures 6, 7). Of note, NK cells eliminate senescent cells, which are considered “stressed”, favoring the clearing of this population and keeping an adequate cell population (48). In support of this hypothesis, NK cells carrying endothelial markers have predominantly degranulated, i.e. they are CD107⁺. This observation is consistent with previous reports describing higher degranulation and expression of activation markers on NK cells that acquired tumor cell markers by trogocytosis, proposing the surface expression of trogocytosed tumor markers as indicative of contact between these NK cells and marker-positive cancer cells (47, 49).

Our observations from *in vitro* experiments strongly imply that transference of HER2, EpCAM and other solid tumor cell markers on NK cells occurs via trogocytosis, proposing this process as the mechanism of capture of epithelial and tumor markers by NK cells under physiological and pathological conditions, as reported in tumor biopsies from BC patients (47). However, it is not possible to definitively conclude that HER2 and the rest of tumor markers found on circulating NK cells from BC patients would have been transferred via trogocytosis. These membrane proteins are normally absent and not expressed by NK cells, and our unsupervised multiparametric analyses found specific subsets of NK cells with high surface levels of these epithelial and solid tumor markers present in blood samples of BC patients; therefore, this correlation should not be completely ruled out, this point remaining pending of further elucidation.

In our study we focused on bona fide NK cells (CD7⁺ CD56⁺ CD3⁻) from patient's peripheral blood. It has been reported that tumor-infiltrating monocytes and NK cells that can be found in breast tumors could show high HER2-trogocytosis, mainly when patients are treated with mAbs systemic treatment, which facilitate NK cell recruitment and activation (47). These observations make us suggest that the amount of Ag capture by trogocytosis on tumor-infiltrating NK cells could be higher and more measurable than the surface levels detected on circulating NKs. However, analysis of infiltrated, tissue-specific human NK populations could prove more challenging and complex (45). For this reason, we did not investigate tissue-specific NK cells that would require biopsies. Hence, we have not probably identified all disease-associated NK populations, but only those that could exit the tumor environment. In addition, we have used a defined panel of NK-associated markers, whereas NK cells can express hundreds of them (50). In summary, other anti-tumor NK populations probably exist and perform degranulation and trogocytosis.

The identification of subsets of circulating NK cells, consisting of activated cells with evident degranulation carrying epithelial and tumor cell markers, raises the issue of the relevance that holds this tumor-trogocytosed marker harboring on NKs cellular and immune functions. Several reports in mice observed that MHC-I acquisition from target cells decreases acceptor NK cell immune recognition and cytotoxic functions (51–54). Correspondingly, it was reported

that human NK cells that capture HLA-G (a non-classical MHC-I immunosuppressive molecule) from melanoma solid tumor cells not only massively reduce their proliferation and their cytotoxicity, but also are able to suppress the cytotoxic function of other bystander NK cells expressing the HLA-G ligand and inhibitory receptor ILT2 (14). Similarly, trogocytosis of CD9 molecules from ovarian carcinoma cells to NK cells renders them less cytotoxic and poorer producers of anti-tumor cytokines, consistent with the identification of a CD9-positive NK cell subset in tubo-ovarian carcinoma samples which presence correlates with tumor progression (55). In line with this, a recent report showed that murine NK cells can acquire by trogocytosis the immune checkpoint inhibitor programmed cell death protein 1 (PD1) from leukemia cells both in vitro and in vivo, suppressing anti-tumor NK cell immunity (20).

However, this might not be the case for tumor receptors like HER2, because similarly to our present results, it has been observed that NK cells co-cultured with trastuzumab-opsonized HER2+ breast cancer cells can acquire HER2 receptor via trogocytosis and exhibit higher expression of CD107a than non-HER2-trogocytosed NK cells (47). In addition, NK cells are capable to obtain the tyrosine kinase receptor TYRO3 from leukemia cells in vitro and in vivo, displaying higher levels of activation markers, enhanced cytotoxicity and interferon-γ secretion (49), thus providing opposing evidence that tumor receptor trogocytosis on NK cells could also translate into gain of anti-tumor activity and effector function (56). This study was focused on the identification of NK cell subsets harboring trogocytosed markers from breast cancer cells, and even if experiments to elucidate the functional outcome of the acquisition of these markers by trogocytosis are pending to perform, we observed high levels of CD107a and low levels of PD1 expression on these NK cells from BC patients, which considering the mentioned literature is consisting with high anti-tumor function of these NK cells.

We have found also that degranulation and trogocytosis is higher in patients that expressed estrogen and/or progesterone receptors. This could be related to the main historical view that triple-negative breast cancer (TNBC) is a cold tumor (57). Hence, it is expected that NK cell infiltration and interaction with tumor target cells is poor in these patients. This should explain the lower level of NK cells that have degranulated and performed trogocytosis in peripheral blood from these patients in our study. However, a larger cohort of patients including both estrogen/progesterone receptor-positive and -negative would be necessary to conclude with greater certain this point.

We expanded our observations by performing dimensionality reduction analysis with viSNE, and we complemented it by using FlowSOM and CITRUS algorithms to further determine NK cell subsets carrying tumor cell antigens. Our unsupervised analyses identified clusters over-represented in BC patients containing tumor markers-expressing NK cells, i.e. metacluster 8. This cluster consisted mostly of CD45RARO⁺ cells, with high level of degranulation that acquired surface expression of tumor markers, most probably by trogocytosis. These cells also exhibited relative
expression levels of PD1, although we found no significative
difference for this marker between BC and HD group (p = 0.61).
Complementing this information, we have observed a very low PD1
levels (from 1% to 5% positive tumor cells) in our cell lines. This
could suggest that PD1 is probably from NK cell origin in our
settings, in accord with previous reports (58). Conversely, we cannot
definitively rule out the likeliness that PD1 expression detected on
NK cells derives from cancer cells, considering that PD1 expression
on tumors derived from BC patients included in this study was not
determined, and it has been already described that in different
experimental settings NK cells can gain also PD1 by trogocytosis
(20). Therefore, one possibility is that PD1 expression could increase
on NK cells once they have acquired cancer cell markers. This could
be due to NK cell activation after recognition of target cells, which
have been reported on both circulating and tumor-infiltrating NK
cells from several types of solid tumors (59–62). We favor this
hypothesis, but we cannot exclude that PD1+ NK cells are more
prone to acquire cancer markers. The physiological relevance could
be important, because PD1+ NK cells with cancer antigens may
participate in maintaining an immunosuppressive state and affect
some immunotherapy treatments. Thus, trogocytosis of these types of
receptors can show strong immunomodulatory capacities on NK cell
immune function and capabilities.

Finally, our *in vitro* approach shows that different Ags are
differently trogocytosed from different target cells and this is
independent of the sensitivity to NK cells. NK cells extract for
example HER2 and EpCAM from SK-BR3 or LNCaP cells; but
almost exclusively EpCAM from HCT116 or BT20 cells.
Meanwhile, the sensitivity of all these cell lines to NK cells was
comparable. Hence, which molecules are trogocytosed depend on
the donor cell and the nature of the molecule. The understanding of
the precise mechanism of trogocytosis will be essential to unveil the
reasons of the disparity between Ags and donor cells.

Data availability statement

The original contributions presented in the study are included
in the article/Supplementary Material. Further inquiries can be
directed to the corresponding author.

Ethics statement

The studies involving human participants were reviewed and
approved by ICM-BDD 2017/37 (ID-RCB: 2017-A01940-53)
clinical program approved by the “Comités de Protection des
Personnes Sud-Ouest et Outre-Mer III”. The patients/participants
provided their written informed consent to participate in this study.

Author contributions

WJ provided essential material and follow patient's status. GG, M-LD and MC performed the experiments. MC-M and MV performed study design and wrote the article. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by the PRT-K program 2021 (MV and GC; 2021-014). This work was also supported by the “Investissements d’avenir” Grant LabEx MAbImprove: ANR-10-LABX-53 (MV).

Acknowledgments

We thank Loïs Coënon for his support in some experiments
described here. We acknowledge the imaging facility MRI, member
of the national infrastructure France-BioImaging supported by the
French National Research Agency (ANR-10-INBS-04, «Investments
for the future»). The “Région Languedoc Roussillon” supports the
clinical data and samples (HEMODIAG_2020).

Conflict of interest

The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors
and do not necessarily represent those of their affiliated
organizations, or those of the publisher, the editors and the
reviewers. Any product that may be evaluated in this article, or
claim that may be made by its manufacturer, is not guaranteed or
endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at:
https://www.frontiersin.org/articles/10.3389/fimmu.2023.1199594/
full#supplementary-material
References

1. Guillerey C. Roles of cytotoxic and helper innate lymphoid cells in cancer. *Mamm Genome Off J Int Mamm Genome Soc* (2018) 29:777-89. doi: 10.1007/s00335-018-9781-4

2. Sivori S, Vacca P, Del Zotto G, Munari E, Mingari MC, Moretta L. Human NK cells: surface receptors, inhibitory checkpoints, and translational applications. *Cell Immunol* (2019) 16:430-41. doi: 10.1038/s41423-019-0206-4

3. Horowitz A, Strauss-Albee DM, Leipold M, Kubo J, Nemat-Gorgani N, Dogan OC, et al. Genetic and environmental determinants of human NK cell diversity revealed by mass cytometry. *Sci Transl Med* (2013) 5:208ra145. doi: 10.1126/scitranslmed.3006702

4. Orrantia A, Terrén I, Astarloa-Pando G, Zenarruzabeitia O, Borrego F. Human NK cells in autologous hematopoietic stem cell transplantation for cancer treatment. *Cancers* (2021) 13:1589. doi: 10.3390/cancers13071589

5. Villalba M, Alexia C, Bellin-Robert A, Fayd'herbe de Maudave A, Gitenay D. Non-genetically improving the natural cytotoxicity of natural killer (NK) cells. *Front Immunol* (2020) 10:3026. doi: 10.3389/fimmu.2019.03026

6. Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. *Nat Rev Drug Discov* (2020) 19:200-18. doi: 10.1038/s41573-019-0052-1

7. Tabiasco J, Espinosa E, Hudrisier D, Joly E, Fournié J-J, Vercellone A. Active trans-synaptic capture of membrane fragments by natural killer cells. *Eur J Immunol* (2002) 32:1502-8. doi: 10.1002/1521-4141(200205)32:5<1502::AID-IMMU1502>3.0.CO;2-Y

8. Miyake K, Karasuyama H. The role of trogocytosis in the modulation of immune cell functions. *Cells* (2021) 10:1255. doi: 10.3390/cells10051255

9. Reed J, Reichelt M, Wetzel SA. Lymphocytes and trogocytosis-mediated signaling. *Cells* (2021) 10:1478. doi: 10.3390/cells10061478

10. Ahmed KA, Munegowda MA, Xie Y, Xiang J. Intercellular trogocytosis plays an important role in modulation of immune responses. *Cell Mol Immunol* (2008) 5:261-9. doi: 10.1038/cmi.2008.32

11. Zhao S, Zhang L, Xiang S, Hu Y, Wu Z, Shen J. Gnawing between cells and cells in the immune system: friend or foe? A review of trogocytosis. *Front Immunol* (2022) 13:791006. doi: 10.3389/fimmu.2022.791006

12. Wakim LM, Bevan MJ. Cross-dressed dendritic cells drive memory CD8+ T-cell activation after viral infection. *Nature* (2011) 471:629-32. doi: 10.1038/nature09863

13. Nakayama M, Takeda K, Kawano M, Takai T, Ishii N, Ogasawara K. Natural killer (NK)-dendritic cell interactions generate MHC class II-dressed NK cells that regulate CD4 + T cells. *Proc Natl Acad Sci USA* (2011) 108:18360-5. doi: 10.1073/pnas.1110584108

14. Caumartin J, Favier B, Daouya M, Guillard C, Moreau P, Carosella ED, et al. Trogocytosis-based generation of suppressive NK cells. *EMBO J* (2007) 26:1423-33. doi: 10.1038/sj.emboj.7601570

15. Miner CA, Giri TK, Meyer CE, Shabsovich M, Tripathy SK. Acquisition of activation receptor ligand by trogocytosis renders NK cells hyporesponsive. *J Immunol* *Baltim Md 1950* (2015) 194:1945-53. doi: 10.4049/jimmunol.1402408

16. Nakamura K, Nakayama M, Kawano M, Ishii T, Harigae H, Ogasawara K. NK-cell fractricide: Dynamic crosstalk between NK and cancer cells. *Oncoimmunology* (2013) 2:e26529. doi: 10.4161/onci.26529

17. Marcenaro E, Cantoni C, Pesce S, Prato C, Pende D, Agaugue S, et al. Uptake of CCR7 and acquisition of migratory properties by human KIR+ NK cells interacting with monocyte-derived DC or EBV cell lines: regulation by KIR/HLA-class I interaction. *Blood* (2009) 114:4108-16. doi: 10.1182/blood-2009-05-222265

18. Li Y, Basar R, Wang G, Liu E, Moyes JS, Li L, et al. KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fractricide and tumor escape. *Nat Med* (2022) 28:2133-44. doi: 10.1038/s41591-022-02003-x

19. Vo D-N, Leventoux N, Campos-Mora M, Gimenez S, Corbeau P, Villalba M. NK cells acquire CCR5 and CXCR4 by trogocytosis in people living with HIV-1. *Vaccines* (2022) 10:688. doi: 10.3390/vaccines10050688

20. Hasim MS, Marotel M, Hodgins JJ, Vulpis E, Makinson OJ, Asif S, et al. When killers become thieves: Trogocytosed PD-1 inhibits NK cells in cancer. *Sci Adv* (2022) 8: eabj3286. doi: 10.1126/sciadv.abj3286

21. Hamieh M, Dobrin A, Cabriolu A, van der Stegen SJC, Giavridis T, Mansilla-Soto J, et al. CAR T cell trogocytosis-mediated fractricide and cooperative killing regulate tumour antigen escape. *Nature* (2019) 568:112-6. doi: 10.1038/s41586-019-1054-1

22. Olson ML, Mause ERV, Radhakrishnan SV, Brody JD, Rapoport AP, Welm AL, et al. Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion. *Leukemia* (2022) 36:1943-6. doi: 10.1038/s41375-022-01585-2

23. Vo DN, Alexia C, Allende-Vega N, Morschhauser F, Houot R, Menard C, et al. NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatment. *Oncoimmunology* (2018) 7:e1409322. doi: 10.1080/2162402X.2017.1409322

24. Vo D-N, Constantinides M, Allende-Vega N, Alexia C, Cartron G, Villalba M. Dissecting the NK cell population in hematological cancers confirms the presence of tumor cells and their impact on NK population function. *Vaccines* (2020) 8(4):727. doi: 10.3390/vaccines8040727

25. Krzywinska E, Cornillon A, Allende-Vega N, Vo DN, Rene C, Lu ZY, et al. CD45 isoform profile identifies natural killer (NK) subsets with differential activity. *PloS One* (2016) 11:e0150434. doi: 10.1371/journal.pone.0150434

26. Krzywinska E, Allende-Vega N, Cornillon A, Vo DN, Cayrefourcq L, Panabieres C, et al. Identification of anti tumor cells carrying natural killer (NK) cell antigens in patients with hematological cancers. *EBioMedicine* (2015) 2:1364-76. doi: 10.1016/j.ebiom.2015.08.021

27. Carrega P, Bonaccorsi I, Di Carlo E, Morandi B, Paul P, Rizzello V, et al. CD56 (bright)perforin(low) noncytotoxic human NK cells are abundant in both healthy and neoplastic solid tissues and recirculate to secondary lymphoid organs via afferent lymph. *J Immunol Baltim Md 1950* (2014) 192:3805-15. doi: 10.4049/jimmunol.1301889

28. Gulubova M, Manolova I, Kyurkchiev D, Julianov A, Altunkova I. Decrease in intrahepatic CD56+ lymphocytes in gastric and colorectal cancer patients with liver metastases. *APMIS Acta Pathol Microbiol Immunol Scand* (2009) 117:870-9. doi: 10.1111/j.1600-0463.2009.02547.x

29. Remark R, Alifano M, Cremer I, Lupo A, Dieu-Nosjean M-C, Riquet M, et al. Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. *Clin Cancer Res Off J Am Assoc Cancer Res* (2013) 19:4079-91. doi: 10.1158/1078-0432.CCR-12-3847

30. Sconocchia G, Arriga R, Tornillo L, Terracciano L, Ferrone S, Spagnoli GC. Melanoma cells inhibit NK cell functions. *Cancer Res* (2012) 72:5428-9. doi: 10.1158/0008-5472.CAN-12-1181

31. Sanchez-Martinez D, Allende-Vega N, Orecchioni S, Talarico G, Cornillon A, Vo DN, et al. Expansion of allogeneic NK cells with efficient antibody-dependent cell cytotoxicity against multiple tumor cells. *Theranostic* (2018) 8:3856-69. doi: 10.7150/thno.25149

32. Reina-Ortiz C, Constantinides M, Fayd-Herbe-de-Maudave A, Présumey J, Hernandez J, Cartron G, et al. Expanded NK cells from umbilical cord blood and adult peripheral blood combined with daratumumab are effective against tumor cells from multiple myeloma patients. *Oncoimmunology* (2020) 10:1853314. doi: 10.1080/2162402X.2020.1853314

33. Allende-Vega N, Marco Brualla J, Falvo P, Alexia C, Constantinides M, de Maudave AF, et al. Metformin sensitizes leukemic cells to cytotoxic lymphocytes by increasing expression of intercellular adhesion molecule-1 (ICAM-1). *Sci Rep* (2022) 12:1341. doi: 10.1038/s41598-022-05470-x

34. Belkahla S, Brualla JM, Fayd'herbe de Maudave A, Falvo P, Allende-Vega N, Constantinides M, et al. The metabolism of cells regulates their sensitivity to NK cells depending on p53 status. *Sci Rep* (2022) 12:3234. doi: 10.1038/s41598-022-07281-6

35. Amir ED, Davis KL, Tadmor MD, Simonds EF, Levine JH, Bendall SC, et al. viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. *Nat Biotechnol* (2013) 31:545-52. doi: 10.1038/nbt.2594

36. Van Gassen S, Callebaut B, Van Helden MJ, Lambrecht BN, Demeester P, Dhaene T, et al. FlowSOM: Using self-organizing maps for visualization and interpretation of cytometry data. *Cytom Part J Int Soc Anal Cytol* (2015) 87:636-45. doi: 10.1002/cyto.a.22625

37. Bruggner RV, Bodenmiller B, Dill DL, Tibshirani RJ, Nolan GP. Automated identification of stratifying signatures in cellular subpopulations. *Proc Natl Acad Sci USA* (2014) 111:E2770-2777. doi: 10.1073/pnas.1408792111

38. Hudrisier D, Riond J, Mazarquall H, Gairin JE, Joly E. Cutting edge: CTLs rapidly capture membrane fragments from target cells in a TCR signaling-dependent manner. *J Immunol Baltim Md 1950* (2001) 166:3645-9. doi: 10.4049/jimmunol.166.6.3645

39. Puaux A-L, Campanaud J, Salles A, Prévillé X, Timmerman B, Joly E, et al. A very rapid and simple assay based on trogocytosis to detect and measure specific T and B cell reactivity by flow cytometry. *Eur J Immunol* (2006) 36:779-88. doi: 10.1002/eji.200535407

40. Aucher A, Magdeleine E, Joly E, Hudrisier D. Capture of plasma membrane fragments from target cells by trogocytosis requires signaling in T cells but not in B cells. *Blood* (2008) 111:5621-8. doi: 10.1182/blood-2008-01-134155

41. Gary R, Voelkl S, Palmisano R, Ullrich E, Bosch JJ, Mackensen A. Antigen-specific transfer of functional programmed death ligand 1 from human APCs onto CD8+ T cells via trogocytosis. *J Immunol Baltim Md 1950* (2012) 188:744-52. doi: 10.4049/jimmunol.1101412

42. Milush JM, Long BR, Snyder-Cappione JE, Cappione AJ, York VA, Ndhlovu LC, et al. Functionally distinct subsets of human NK cells and monocyte/DC-like cells identified by coexpression of CD56, CD7, and CD4. *Blood* (2009) 114:4823-31. doi: 10.1182/blood-2009-04-216374

43. Becher B, Schlitzer A, Chen J, Mair F, Sumatoh HR, Teng KWW, et al. High-dimensional analysis of the murine myeloid cell system. *Nat Immunol* (2014) 15:1181-9. doi: 10.1038/ni.3006

44. Gaudillière B, Fragiadakis GK, Bruggner RV, Nicolau M, Finck R, Tingle M, et al. Clinical recovery from surgery correlates with single-cell immune signatures. *Sci Transl Med* (2014) 6:255ra131. doi: 10.1126/scitranslmed.3009701

45. Freud AG, Mundy-Bosse BL, Yu J, Caligiuri MA. The broad spectrum of human natural killer cell diversity. *Immunity* (2017) 47:820-33. doi: 10.1016/j.immuni.2017.10.008

46. Strauss-Albee DM, Blish CA. Human NK cell diversity in viral infection: ramifications of ramification. *Front Immunol* (2016) 7:66. doi: 10.3389/fimmu.2016.00066
47. Suzuki E, Kataoka TR, Hirata M, Kawaguchi K, Nishie M, Haga H, et al. Trogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patients. *BMC Cancer* (2015) 15:39. doi: 10.1186/s12885-015-1041-3

48. Antonangeli F, Zingoni A, Soriani A, Santoni A. Senescent cells: Living or dying is a matter of NK cells. *J Leukoc Biol* (2019) 105:1275-83. doi: 10.1002/JLB.MR0718-299R

49. Lu T, Ma R, Li Z, Mansour AG, Teng K-Y, Chen L, et al. Hijacking TYRO3 from tumor cells via trogocytosis enhances NK-cell effector functions and proliferation. *Cancer Immunol Res* (2021) 9:1229-41. doi: 10.1158/2326-6066.CIR-20-1014

50. Béziat V, Liu LL, Malmberg J-A, Ivarsson MA, Sohlberg E, Björklund AT, et al. NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs. *Blood* (2013) 121:2678-88. doi: 10.1182/blood-2012-10-459545

51. Zimmer J, Ioannidis V, Held W. H-2D ligand expression by Ly49A+ natural killer (NK) cells precludes ligand uptake from environmental cells: implications for NK cell function. *J Exp Med* (2001) 194:1531-9. doi: 10.1084/jem.194.10.1531

52. Carlin LM, Eleme K, McCann FE, Davis DM. Intercellular transfer and supramolecular organization of human leukocyte antigen C at inhibitory natural killer cell immune synapses. *J Exp Med* (2001) 194:1507-17. doi: 10.1084/jem.194.10.1507

53. Sjöström A, Eriksson M, Cerboni C, Johansson MH, Sentman CL, Kärre K, et al. Acquisition of external major histocompatibility complex class I molecules by natural killer cells expressing inhibitory Ly49 receptors. *J Exp Med* (2001) 194:1519-30. doi: 10.1084/jem.194.10.1519

54. Vanherberghen B, Andersson K, Carlin LM, Nolte-’t Hoen ENM, Williams GS, Höglund P, et al. Human and murine inhibitory natural killer cell receptors transfer from natural killer cells to target cells. *Proc Natl Acad Sci USA* (2004) 101:16873-8. doi: 10.1073/pnas.0406240101

55. Gonzalez VD, Huang Y-W, Delgado-Gonzalez A, Chen S-Y, Donoso K, Sachs K, et al. High-grade serous ovarian tumor cells modulate NK cell function to create an immune-tolerant microenvironment. *Cell Rep* (2021) 36:109632. doi: 10.1016/j.celrep.2021.109632

56. Mattei F, Andreone S, Spadaro F, Noto F, Tinari A, Falchi M, et al. Trogocytosis in innate immunity to cancer is an intimate relationship with unexpected outcomes. *iScience* (2022) 25:105110. doi: 10.1016/j.isci.2022.105110

57. Carlino F, Diana A, Piccolo A, Ventriglia A, Bruno V, De Santo I, et al. Immune-based therapy in triple-negative breast cancer: from molecular biology to clinical practice. *Cancers* (2022) 14:2102. doi: 10.3390/cancers14092102

58. Davis Z, Felices M, Lenvik T, Badal S, Walker JT, Hinderlie P, et al. Low-density PD-1 expression on resting human natural killer cells is functional and upregulated after transplantation. *Blood Adv* (2021) 5:1069-80. doi: 10.1182/bloodadvances.2019001110

59. MacFarlane AW, Jillab M, Plimack ER, Hudes GR, Uzzo RG, Litwin S, et al. PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection. *Cancer Immunol Res* (2014) 2:320-31. doi: 10.1158/2326-6066.CIR-13-0133

60. Trefny MP, Kaiser M, Stanczak MA, Herzig P, Savic S, Wiese M, et al. PD-1+ natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade. *Cancer Immunol Immunother CII* (2020) 69:1505-17. doi: 10.1007/s00262-020-02558-z

61. Liu Y, Cheng Y, Xu Y, Wang Z, Du X, Li C, et al. Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers. *Oncogene* (2017) 36:6143-53. doi: 10.1038/onc.2017.209

62. Quatrini L, Vacca P, Tumino N, Besi F, Di Pace AL, Scordamaglia F, et al. Glucocorticoids and the cytokines IL-12, IL-15, and IL-18 present in the tumor microenvironment induce PD-1 expression on human natural killer cells. *J Allergy Clin Immunol* (2021) 147:349-60. doi: 10.1016/j.jaci.2020.04.044